Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny+6 more
core +1 more source
Nanoparticles in the treatment of chronic lung diseases [PDF]
Nanoparticles, although considered a topic of modern medicine, actually have an interesting history. Currently, advances in nanomedicine hold great promise as drug carrier systems for sustained release and targeted delivery of diverse therapeutic agents.
Alexescu, Teodora G+9 more
core +2 more sources
Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE) [PDF]
Background: Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation.
Baraldi F.+13 more
core +1 more source
Update on Biological Therapeutics for Asthma [PDF]
: Asthma poses a significant burden on patients, families, health care providers, and the medical system. While efforts to standardize care through guidelines have expanded, difficulty in managing severe asthma has encouraged research about its ...
Bruce S. Bochner, Marisha L. Cook
core +1 more source
Recent years have seen an increase in use of mepolizumab and other biological therapies for the treatment of severe eosinophilic asthma. A few cases of paradoxical responses to mepolizumab therapy have now been reported and are hypothesised as being a response to immune complex formation.
Raquel Despiney+2 more
openaire +3 more sources
Corticosteroids: still at the frontline in asthma treatment? [PDF]
Inhaled corticosteroids (ICS) have led to improved asthma control and reduced asthma mortality in the Western world. ICS are effective in combating T-helper type 2-driven inflammation featuring mast cell and eosinophilic airway infiltration. Their effect
Barnes, Peter J.+2 more
core +1 more source
Severe Pediatric Asthma Therapy: Mepolizumab
There is a growing need for advanced treatment in children with persistent and severe asthma symptoms. As a matter of fact, between 2 and 5% of asthmatic children experience repeated hospitalizations and poor quality of life despite optimized treatment with inhaled glucocorticoid plus a second controller.
Nicola Ullmann+8 more
openaire +3 more sources
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe+4 more
core +3 more sources
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard+4 more
core +4 more sources
Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]
Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy+4 more
core +3 more sources